Brain metastases in NSCLC

Recent studies in NSCLC patients with ALK or EGFR mutations and brain metastases, demonstrated greater benefit from the use of specific targeted therapies. In this Podcast, Associate Professor Paul Mitchell, Medical Oncologist from the Olivia Newton-John Cancer Centre, is joined by Dr Fiona Hegi-Johnson, Radiation Oncologist, Peter MacCallum Cancer Centre in Victoria, and Dr Dasantha Jayamanne, Radiation Oncologist, Genesis Care and Royal Northshore Hospital in NSW to discuss the management of brain metastases in NSCLC. They discuss the current data, the role of stereotactic radiation therapy (SRS, SABR, SBRT) and molecular drivers of ALK and EGFR in the management of these patients. Complex care is also discussed, as are intricacies and clinical considerations behind choosing and implementing care in NSCLC patients with brain metastases. Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube:  https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.